Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
- 1 August 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 20 (8), e452-e463
- https://doi.org/10.1016/s1470-2045(19)30171-8
Abstract
No abstract availableKeywords
This publication has 112 references indexed in Scilit:
- Controversies and challenges regarding the impact of radiation therapy on survivalAnnals Of Oncology, 2013
- Image-guided radiotherapy: from current concept to future perspectivesNature Reviews Clinical Oncology, 2012
- Toll-like Receptor 5 Agonist Protects Mice From Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer RadiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 2012
- TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer CellsIn Vitroand Promotes Tumor Control by RadiationIn VivoClinical Cancer Research, 2011
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsThe Journal of Experimental Medicine, 2011
- Effect of total body irradiation on late lung effects: Hidden dangersInternational Journal of Radiation Biology, 2011
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialThe Lancet Oncology, 2011
- Radiation Enhances Regulatory T Cell RepresentationInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directionsNature Clinical Practice Oncology, 2007